嗜铬细胞瘤的CT特征:对肾上腺意外瘤评估的意义
本多中心回顾性研究由两名中心研究者独立分析533例患者共548个经组织学确诊嗜铬细胞瘤的CT报告,收集肿瘤大小、平扫CT值、绝对与相对对比剂廓清率等数据。结果显示,有平扫CT值资料的376个嗜铬细胞瘤中374个(99.5%)平扫CT值>10 HU,仅2个(0.5%)恰为10 HU;在有平扫CT值>10 HU及廓清资料的76个嗜铬细胞瘤中,22个(28.9%)呈提示肾上腺皮质腺瘤的高廓清率。
要点
- 平扫CT值≤10 HU的肾上腺意外瘤中嗜铬细胞瘤比例极低(0.5%),可考虑不做生化排查。
- 平扫CT值>10 HU者中28.9%出现提示腺瘤的高对比剂廓清率。
- 对比剂廓清率评估不可靠,不能用于排除嗜铬细胞瘤。
核心结论
- 基于本研究中无平扫CT值<10 HU的嗜铬细胞瘤、且仅0.5%的嗜铬细胞瘤平扫CT值为10 HU,对平扫CT值≤10 HU的肾上腺意外瘤可不做嗜铬细胞瘤生化检测。
- 对比剂廓清率评估用于排除嗜铬细胞瘤并不可靠。
研究设计与样本
- 多中心回顾性研究,两名中心研究者独立分析533例患者共548个经组织学确诊的嗜铬细胞瘤的CT报告。
- 收集肿瘤大小、平扫CT值(HU)、绝对百分比廓清率(APW)、相对百分比廓清率(RPW)及临床参数。
主要发现
- 有平扫CT值资料的376个嗜铬细胞瘤中,374个(99.5%)平扫CT值>10 HU。
- 仅2个(0.5%)平扫CT值恰为10 HU,落在提示肾上腺皮质腺瘤的≤10 HU范围内。
- 有平扫CT值>10 HU及廓清资料的76个嗜铬细胞瘤中,22个(28.9%)APW和/或RPW升高,提示腺瘤。
关键数值与推荐
- 提示肾上腺皮质腺瘤的平扫CT值范围为≤10 HU。
- 平扫CT值>10 HU且APW和/或RPW升高者共22/76(28.9%)。
临床怎么用
- 对平扫CT值≤10 HU的肾上腺意外瘤,可考虑不做嗜铬细胞瘤生化排查。
- 不应依据对比剂廓清率排除嗜铬细胞瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the evaluation of AI, it is generally recommended that PCC be excluded by measurement of plasma-free or 24-hour urinary fractionated metanephrines. However, recent studies suggest that biochemical exclusion of PCC not be performed for lesions with CT characteristics of an adrenocortical adenoma (ACA). AIM: To determine the proportion of PCCs with ACA-like attenuation or contrast washout on CT. METHODS: For this multicenter retrospective study, two central investigators independently analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor size, unenhanced Hounsfield units (HU), absolute percentage washout (APW), and relative percentage washout (RPW) were collected in addition to clinical parameters. RESULTS: Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an attenuation of >10 HU (99.5%). In the two exceptions (0.5%), unenhanced attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA. Of 76 PCCs with unenhanced HU > 10 and available washout data, 22 (28.9%) had a high APW and/or RPW, suggestive of ACA. CONCLUSION: Based on the lack of PCCs with an unenhanced attenuation of <10 HU and the low proportion (0.5%) of PCCs with an attenuation of 10 HU, it seems reasonable to abstain from biochemical testing for PCC in AIs with an unenhanced attenuation of ≤10 HU. The assessment of contrast washout, however, is unreliable for ruling out PCC.
引用
- Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019. PMID: 30383267. doi:10.1210/jc.2018-01532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。